Eculizumab treatment in paroxysmal nocturnal hemoglobinuria
B Sallerfors, T Franzén, L Jansson, N Kuric, P Olsson, P Sjögren, T Svanberg, B Widgren, H Sjövall
Record ID 32013000132
English
Authors' objectives:
Does treatment with eculizumab reduce mortality, reduce the need for blood transfusions, reduce the risk for thromboembolic events and increase quality of life (QOL) in PNH patients with or without anemia, as compared to standard treatment with blood transfusions and if indicated anticoagulation?
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.sahlgrenska.se/upload/SU/HTA-centrum/HTA-rapporter/HTA-report%20Soliris%20%20incl%20app,%20statement%20%202012-01-23%20publicerad.pdf
URL for additional information:
http://www.sahlgrenska.se/sv/SU/Forskning/HTA-centrum/Hogerkolumn-undersidor/Publicerade-rapporter/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
MeSH Terms
- Antibodies, Monoclonal, Humanized
- Hemoglobinuria, Paroxysmal
- Complement Inactivating Agents
Contact
Organisation Name:
The Regional Health Technology Assessment Centre
Contact Address:
The Regional Health Technology Assessment Centre, Region Vastra Gotaland, HTA-centrum, Roda Straket 8, Sahlgrenska Universitetssjukhuset, 413 45 GOTHENBORG, Sweden
Contact Name:
hta-centrum@vgregion.se
Contact Email:
hta-centrum@vgregion.se
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.